SCHEMBL21541797

SCHEMBL21541797

CN(C)C1CCN(c2ccc(-c3ccc4ncc5nnc(N6CCCCC6)n5c4n3)cc2F)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 5/20 0.37
▸ CSF1R P07333 5/20 0.37
▸ CDK4 P11802 5/20 0.37
▸ CDK6 Q00534 5/20 0.37
▸ CCNK O75909 1/20 0.35
▸ CCNA2 P20248 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ CDK7 P50613 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ CCNH P51946 1/20 0.35
▸ CDK5 Q00535 1/20 0.35
▸ CDK5R1 Q15078 1/20 0.35
▸ KDM1A O60341 2/20 0.35
▸ MET P08581 2/20 0.34
▸ PDE3B Q13370 2/20 0.34
▸ PDE3A Q14432 2/20 0.34
▸ FFAR4 Q5NUL3 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ JAK2 O60674 3/20 0.34
▸ BRD4 O60885 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21541845 0.97 PIK3CD (0.38) PIK3CDCSF1RCDK4CDK6CCNK
SCHEMBL21541846 0.91 KMO (0.39) KDM1AMETPDE3BPDE3ADYRK1A
SCHEMBL21541808 0.90 S1PR1 (0.37) CSF1RCDK4CDK6CCNA2CDK2
SCHEMBL21541749 0.89 CSF1R (0.37) PIK3CDCSF1RCDK4CDK6CCNK
SCHEMBL21541802 0.89 CSF1R (0.37) PIK3CDCSF1RCDK4CDK6CCNK
SCHEMBL21541893 0.87 MELK (0.37) KDM1AMETPDE3BPDE3AMELK
SCHEMBL21541733 0.86 CDK4 (0.37) CSF1RCDK4CDK6CCNA2CDK2
SCHEMBL21541904 0.86 PRKDC (0.40) PIK3CDCSF1RCDK4CDK6CCNK
SCHEMBL21541761 0.86 KCNH2 (0.37) CDK4CDK6KDM1AMETPDE3B
SCHEMBL21541815 0.82 SYK (0.38) CDK4CDK6KDM1AMETPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3567041-A9 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2022-04-20 — — EP disclosed
US-10874670-B2 Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof IMPACT THERAPEUTICS, INC. (CN) 2020-12-29 — — US disclosed
EP-3567041-A1 SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF Impact Therapeutics, Inc (CN) 2019-11-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874670-B2 Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof CHEK1, CHEK2, CDK1 PIK3CD 149/4885CSF1R 2386/4885CDK4 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback